Mardiah Suci Hardianti * Corresponding Author Division of Hematology-Medical Oncology, Department of Internal Medicine, Dr. Sardjito General Hospital/ Faculty of Medicine Universitas Gadjah Mada, Yogyakarta, Indonesia
Johan Kurnianda Division of Hematology-Medical Oncology, Department of Internal Medicine, Dr. Sardjito General Hospital/ Faculty of Medicine Universitas Gadjah Mada, Yogyakarta, Indonesia
Kartika Widayati Taroeno-Hariadi Division of Hematology-Medical Oncology, Department of Internal Medicine, Dr. Sardjito General Hospital/ Faculty of Medicine Universitas Gadjah Mada, Yogyakarta, Indonesia
Mardiah Suci Hardianti(1*), Johan Kurnianda(2), Kartika Widayati Taroeno-Hariadi(3)
(1) Division of Hematology-Medical Oncology, Department of Internal Medicine, Dr. Sardjito General Hospital/ Faculty of Medicine Universitas Gadjah Mada, Yogyakarta, Indonesia (2) Division of Hematology-Medical Oncology, Department of Internal Medicine, Dr. Sardjito General Hospital/ Faculty of Medicine Universitas Gadjah Mada, Yogyakarta, Indonesia (3) Division of Hematology-Medical Oncology, Department of Internal Medicine, Dr. Sardjito General Hospital/ Faculty of Medicine Universitas Gadjah Mada, Yogyakarta, Indonesia (*) Corresponding Author
Abstract
A rising number of long-term survivors and potential long-term outcome related to the treatment is one of the most important issue due to the advances of management in cancer. The development of secondary malignancy has been reported in a number of cohorts. We present a case of breast cancer patient developing acute myeloid leukemia (AML)- M5 within a relatively short interval of two and a half years from her primary treatment with adjuvant chemotherapy with 4 cycles of doxorubicin and cyclophosphamide, followed by 4 cycles of three weekly paclitaxel (AC-T) and radiotherapy. What could be attributed to the occurrence of secondary leukemia in this patient will be discussed.
Keywords
breast cancer- secondary leukemia- adjuvant chemotherapy-radiotherapy-breast cancer